

# Next-gen diagnostics systems, 10/16

## **At the AACCC show 2016**

**October 2016**—Abbott introduced Alinity, its harmonized family of next-generation systems across immunoassay, clinical chemistry, point-of-care, hematology, blood and plasma screening, and molecular diagnostics. Each Alinity platform will include a number of features to help institutions, clinicians, and laboratorians better navigate through the health care environment. Designed with universal, intuitive interfaces as well as common software and hardware, the Alinity systems will have the ability to work together, providing greater capacity and simplifying the user experience. Several of the platforms will be designed to run more tests in less space, generate test results faster, and minimize human errors. By offering a comprehensive solution that addresses the challenges of using multiple diagnostics platforms while continuing to provide quality results that positively impact patient care, Alinity could potentially change the industry's testing paradigm, according to a company statement.

"Abbott's Alinity portfolio is unprecedented in the industry," said Brian Blaser, executive vice president of diagnostics products, Abbott. "With our unified family of testing instruments, we'll be able to offer more efficiency, flexibility, and confidence to health systems and better help doctors and nurses get the results they need to improve decision-making and patient care."

Abbott expects Alinity launches to begin later this year and continue into 2017. The systems are supported by Abbott's AlinIQ, a combined professional services and informatics solution that assists labs in achieving greater operational productivity with their existing resources.

**[Abbott Diagnostics](#)**, 877-423-3688